MD-OncoMD-OncoMD-Onco2782-32022782-6171Publishing House ABV Press6710.17650/2782-3202-2023-3-2-16-19NEW DIRECTIONS AND ADVANCEMENTS IN TREATMENT OF ONCOLOGICAL DISEASES IN THE CURRENT AGEНОВЫЕ НАПРАВЛЕНИЯ И УСПЕХИ В ЛЕЧЕНИИ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ НА СОВРЕМЕННОМ ЭТАПЕPerspectives and possibilities of preserving reproductive function in patients receiving antitumor treatment. Clinical observationПерспективы и возможности сохранения репродуктивной функции у больных, получающих противоопухолевое лечение. Клиническое наблюдениеKutakovN. M.КутаковН. М.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

ChekiniD. A.ЧекиниД. А.
Russian Federation

Jennet Ashirovna Chekini

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Дженнет Ашировна Чекини

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

d.chekini@mcclinics.ruClinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»220520233216192005202320052023Copyright ©; 2023, ABV-PressCopyright ©; 2023, АБВ-пресс2023ABV-PressАБВ-прессhttps://mdonco.abvpress.ru/jour/about/editorialPolicieshttps://mdonco.abvpress.ru/jour/article/view/67

Currently, treatment of patients with early primary operable BRCA mutation-associated breast cancer requires integrative approach. A mutation in BRCA1/2 genes is a prognostically unfavorable factor increasing the risk of cancer of the contralateral breast, as well as ovaries, pancreas, fallopian tubes, and primary peritoneal cancer. In this clinical observation, an integrative multidisciplinary approach to treatment of a young patient with luminal B breast cancer is described which allowed to preserve the patient’s fertility and achieve pregnancy using assisted reproductive technologies.

High effectiveness of the chosen treatment tactics in the framework of integrative approach in a specialized medical facility with experience in treatment of oncological diseases and preservation of reproductive function confirmed by clinical data and results of laboratory and instrumental exams is demonstrated.

В настоящее время лечение пациенток с ранним первично-операбельным BRCA-ассоциированным раком молочной железы требует комплексного подхода. Наличие мутации в генах BRCA1/2 является прогностически неблагоприятным фактором, повышающим риск развития рака контралатеральной молочной железы, а также рака яичников, поджелудочной железы, фаллопиевых труб и первичного рака брюшины. В статье представлен клинический случай молодой пациентки с диагнозом рака молочной железы люминального В подтипа. Описан комплексный мультидисциплинарный подход к лечению, результатом которого стало успешное сохранение фертильности с последующим наступлением беременности с помощью вспомогательных репродуктивных технологий.

Продемонстрирована высокая эффективность выбранной лечебной тактики при комплексном подходе в одном специализированном лечебном учреждении с опытом работы в сфере лечения онкологических заболеваний и сохранения репродуктивной функции, подтвержденная клиническими данными, а также результатами лабораторно-инструментальных исследований.

breast cancerchemotherapyhormone therapypregnancyBRCA1/2 mutationрак молочной железыхимиотерапиягормонотерапиябеременностьмутация BRCA1/21. Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30. DOI: 10.1086/375033Antoniou A., Pharoah P.D., Narod S. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003;72(5):1117–30. DOI: 10.1086/3750332. Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25(11):1329–33. DOI: 10.1200/JCO.2006.09.1066Chen S., Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25(11):1329–33. DOI: 10.1200/JCO.2006.09.10663. Chen J., Bae E., Zhang L. et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-ophorectomy: an updated meta-analysis. JNCI Cancer Spectr 2020;4(4):pkaa029. DOI: 10.1093/jncics/pkaa029Chen J., Bae E., Zhang L. et al. Penetrance of breast and ovarian cancer in women who carry a BRCA1/2 mutation and do not use risk-reducing salpingo-ophorectomy: an updated meta-analysis. JNCI Cancer Spectr 2020;4(4):pkaa029. DOI: 10.1093/jncics/pkaa0294. Baretta Z., Mocellin S., Goldin E. et al. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95(40):e4975. DOI: 10.1097/MD.0000000000004975Baretta Z., Mocellin S., Goldin E. et al. Effect of BRCA germline mutations on breast cancer prognosis: a systematic review and meta-analysis. Medicine (Baltimore) 2016;95(40):e4975. DOI: 10.1097/MD.00000000000049755. Copson E.R., Maishman T.C., Tapper W.J. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018;19(2):169–80. DOI: 10.1016/S1470-2045(17)30891-4Copson E.R., Maishman T.C., Tapper W.J. et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study. Lancet Oncol 2018;19(2):169–80. DOI: 10.1016/S1470-2045(17)30891-46. Garcia-Etienne C.A., Barile M., Gentilini O.D. et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16(12):3380–7. DOI: 10.1245/s10434-009-0638-7Garcia-Etienne C.A., Barile M., Gentilini O.D. et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009;16(12):3380–7. DOI: 10.1245/s10434-009-0638-77. Chabner E., Nixon A., Gelman R. et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1998;16(6):2045–51. DOI: 10.1200/JCO.1998.16.6.2045Chabner E., Nixon A., Gelman R. et al. Family history and treatment outcome in young women after breast-conserving surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1998;16(6):2045–51. DOI: 10.1200/JCO.1998.16.6.20458. Bedrosian I., Hu C.Y., Chang G.J. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010;102(6):401–9. DOI: 10.1093/jnci/djq018Bedrosian I., Hu C.Y., Chang G.J. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 2010;102(6):401–9. DOI: 10.1093/jnci/djq0189. Lostumbo L., Carbine N.E., Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010;(11):CD002748. DOI: 10.1002/14651858.CD002748.pub3Lostumbo L., Carbine N.E., Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev 2010;(11):CD002748. DOI: 10.1002/14651858.CD002748.pub310. Domchek S.M., Friebel T.M., Singer C.F. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304(9):967–75. DOI: 10.1001/jama.2010.1237Domchek S.M., Friebel T.M., Singer C.F. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304(9):967–75. DOI: 10.1001/jama.2010.123711. Rebbeck T.R., Lynch H.T., Neuhausen S.L. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346(21):1616–22. DOI: 10.1056/NEJMoa012158Rebbeck T.R., Lynch H.T., Neuhausen S.L. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346(21):1616–22. DOI: 10.1056/NEJMoa01215812. Kauff N.D., Satagopan J.M., Robson M.E. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346(21):1609–15. DOI: 10.1056/NEJMoa020119Kauff N.D., Satagopan J.M., Robson M.E. et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346(21):1609–15. DOI: 10.1056/NEJMoa02011913. Marchetti C., De Felice F., Palaia I. et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA1 and BRCA2 mutation carriers. BMC Womens Health 2014;14:150. DOI: 10.1186/s12905-014-0150-5Marchetti C., De Felice F., Palaia I. et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA1 and BRCA2 mutation carriers. BMC Womens Health 2014;14:150. DOI: 10.1186/s12905-014-0150-514. Revelli A., Salvagno F., Delle Piane L. et al. Fertility preservation in BRCA mutation carriers. Minerva Ginecol 2016;68(5):587–601. PMID: 26997146.Revelli A., Salvagno F., Delle Piane L. et al. Fertility preservation in BRCA mutation carriers. Minerva Ginecol 2016;68(5):587–601. PMID: 26997146.15. Telfer E.E., Andersen C.Y. In vitro growth and maturation of primordial follicles and immature oocytes. Fertil Steril 2021;115(5):1116–25 DOI: 10.1016/j.fertnstert.2021.03.004Telfer E.E., Andersen C.Y. In vitro growth and maturation of primordial follicles and immature oocytes. Fertil Steril 2021;115(5):1116–25 DOI: 10.1016/j.fertnstert.2021.03.00416. About Ovarian Tissue Freezing. Available at: https://www.mskcc.org/cancer-care/patient-education/ovarian-tissue-freezingAbout Ovarian Tissue Freezing. Available at: https://www.mskcc.org/cancer-care/patient-education/ovarian-tissue-freezing